Rapt Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
RAPT Therapeutics, Inc. has completed its merger with GlaxoSmithKline LLC's subsidiary, Redrose Acquisition Co., becoming a wholly-owned entity.
GSK announced a definitive agreement to acquire RAPT Therapeutics for $58.00 per share in cash, valuing the company at approximately $2.2 billion, to gain its lead asset ozureprubart for food allergies.
RAPT Therapeutics presented positive Phase 2 data for ozureprubart in Chronic Spontaneous Urticaria and outlined plans for pivotal trials and a Phase 2b food allergy study, projecting a cash runway into mid-2028.
RAPT Therapeutics announces the mutual agreement for Dr. William Ho, Chief Medical Officer, to depart on December 31, 2025, and transition into a strategic consulting role.
RAPT Therapeutics announced its third quarter 2025 financial results, highlighted by positive Phase 2 CSU data, initiation of a Phase 2b food allergy trial, and a $250 million public offering.
RAPT Therapeutics, Inc. announced an underwritten public offering of 8,333,334 shares of common stock at $30.00 per share, aiming to raise approximately $234.4 million in net proceeds.
RAPT Therapeutics and Jeyou announced positive topline Phase 2 data for RPT904 in chronic spontaneous urticaria, showing comparable efficacy and safety to omalizumab with less frequent dosing.
RAPT Therapeutics reported a significantly reduced net loss for Q2 2025 and the first half of the year, while confirming key clinical trials remain on track for the second half of 2025.
RAPT Therapeutics highlights its next-generation anti-IgE antibody, RPT904, as a potential best-in-class therapy for food allergy and chronic spontaneous urticaria, supported by positive Phase 1 data and significant market opportunities.
RAPT Therapeutics, Inc. announced the expansion of its Board of Directors and the appointment of Dr. Scott Braunstein and Dr. Ashley Dombkowski, bringing extensive industry and executive experience.
RAPT Therapeutics, Inc. has officially implemented a 1-for-8 reverse stock split of its common stock, effective June 16, 2025, following stockholder approval.
RAPT Therapeutics highlights its novel anti-IgE antibody, RPT904, designed for less frequent dosing than omalizumab, targeting multi-billion dollar markets in Food Allergy and Chronic Spontaneous Urticaria with key clinical milestones anticipated through 2027.
RAPT Therapeutics, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including new equity incentive plans, the re-election of a director, and a proposal for a reverse stock split.
RAPT Therapeutics, Inc. received a Nasdaq notification for failing to meet the minimum $1.00 bid price requirement, prompting a proposed one-for-eight reverse stock split to regain compliance.
RAPT Therapeutics announces its first quarter 2025 financial results, noting a reduced net loss and progress in its RPT904 clinical development program.
Dr. Wendye R. Robbins will not seek re-election at RAPT Therapeutics' 2025 annual meeting, leading to a reduction in the board size.
RAPT Therapeutics announces its Q4 and full-year 2024 financial results, highlighting a net loss but emphasizing the advancement of RPT904 for food allergy and chronic spontaneous urticaria.
RAPT Therapeutics is advancing its pipeline, particularly RPT904 for food allergy and chronic spontaneous urticaria, and developing a next-generation oral CCR4 antagonist.
RAPT Therapeutics reports the resignation of William Rieflin from the Board of Directors and the appointment of Lori Lyons-Williams as the new Chair, effective January 5, 2025.
RAPT Therapeutics has entered into a licensing agreement with Shanghai Jemincare for an anti-IgE monoclonal antibody and secured $150 million through a private placement to advance its pipeline.
8-K: RAPT Therapeutics Secures $150 Million in Private Placement and Licenses Novel Anti-IgE Antibody
RAPT Therapeutics has announced a $150 million private placement and an exclusive licensing agreement with Shanghai Jemincare Pharmaceutical for a novel anti-IgE antibody, RPT904.
RAPT Therapeutics has repriced underwater stock options for employees and consultants to a new exercise price of $1.57, aiming to retain and motivate key personnel.
RAPT Therapeutics announced a reduced net loss for the third quarter of 2024, alongside a significant workforce reduction to conserve cash.
RAPT Therapeutics announced its second quarter 2024 financial results, alongside a workforce reduction of 40% to conserve cash, while continuing to analyze data from halted clinical trials.
RAPT Therapeutics will reduce its workforce by approximately 40% to conserve cash, incurring an estimated $0.9 million in restructuring charges.
RAPT Therapeutics held its 2024 annual meeting, electing three Class II directors and ratifying Ernst & Young LLP as its independent auditor for the fiscal year ending December 31, 2024.
RAPT Therapeutics has stopped its Phase 2 trials for zelnecirnon due to a serious adverse event, while also reporting a net loss of $30.5 million for the first quarter of 2024.
RAPT Therapeutics reported a net loss of $116.8 million for 2023, with increased research and development expenses, while also facing a clinical hold on key trials.
RAPT Therapeutics has received verbal notification from the FDA of a clinical hold on its Phase 2b trial for atopic dermatitis and Phase 2a trial for asthma using zelnecirnon.
RAPT Therapeutics has announced a clinical hold on its Phase 2b atopic dermatitis and Phase 2a asthma trials for zelnecirnon (RPT193) following a serious adverse event of liver failure in one patient.